GlassScriptPhysician profile
Anna S Bhatnagar
NPI 1467000729
$2,759.94
in general payments reported to CMS, 2019-2025
29 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $608 · 2023: $311 · 2024: $443 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $455.06 | 2021-2025 | Resolute Onyx, Micra, Mycarelink |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $274.00 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $227.90 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $197.60 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $196.79 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $156.72 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $146.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $145.03 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $129.47 | 2022-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $103.98 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $96.78 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $86.61 | 2021-2022 | |
| Amarin Pharma, INC. | $83.31 | 2021 | |
| Chiesi USA, INC. | $66.84 | 2021-2023 | Cleviprex, Kengreal |
| E.R. Squibb & Sons, L.L.C. | $64.54 | 2023-2025 | Eliquis, Camzyos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $55.71 | 2021-2023 | Definity |
| Abbott Laboratories | $38.57 | 2024-2025 | Cardiomems, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.65 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.43 | 2022 | |
| Irhythm Technologies, INC. | $23.01 | 2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $21.68 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2021 | |
| Esperion Therapeutics, INC. | $18.93 | 2021 | |
| Abiomed | $18.36 | 2025 | |
| Baxter Healthcare | $17.80 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $15.91 | 2025 | |
| Atricure, INC. | $15.85 | 2021 | |
| Cvrx, INC. | $15.63 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.78 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.